title: [Efficacy of whole body gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer].
abstract: OBJECTIVE
  Radiotherapy and chemotherapy are major therapies for locally advanced pancreatic cancer. This study was to evaluate the efficacy of three-dimensional conformal gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer.
  
  
  METHODS
  From December 2001 to January 2006, 75 patients with locally advanced pancreatic cancer were divided into radiotherapy group (37 patients) and combination group (38 patients). All patients received gamma-knife radiotherapy using Stereotactic Radiotherapy Gamma Rays System, with iso-dose curves of 50%-60%, tumor encircling dose of 3.0-4.5 Gy per fraction, 8-11 fractions. The patients in combination group received simultaneous thermotherapy at 41.5-43.5 celsius (1 h/fraction, twice a week for 6 times), and chemotherapy with venous administration of tegafur (0.5-1.0 g) and calcium folinate (CF, 0.2 g) for 4-6 times, or venous administration of gemcitabine (0.6-1.0 g/m2) on Days 1 and 8 and cisplatin (DDP) (20-30 mg/m2) on Days 1-3, repeated every 28 days for 3-6 cycles.
  
  
  RESULTS
  At 3 months after treatment, the total response (complete remission and partial remission) rate was 70.7% (53/75); the response rate was 73.7% in combination group and 67.5% in radiotherapy group. The 1-year survival rate was 48.3%, and the 2-year survival rate was 22.1%. The 1-and 2-year survival rates were 51.2% and 26.5% in combination group, and 45.2% and 17.6% in radiotherapy group. No serious complications, such as perforation, bleeding and high fever, were seen during treatment and follow-up.
  
  
  CONCLUSIONS
  3-D conformal gamma-knife radiotherapy combined with thermochemotherapy is well tolerated and is relatively effective for most patients with locally advanced pancreatic cancer.
authors.affiliation: Department of Radiation Oncology, Naval General Hospital of PLA, Beijing, China.
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Zhang
authors.forename: Qing
authors.initials: Q
authors.lastname: Nie
authors.forename: Jing-Bo
authors.initials: JB
authors.lastname: Kang
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
authors.forename: Chang-Lan
authors.initials: CL
authors.lastname: Cai
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Li
authors.forename: Wen-Jie
authors.initials: WJ
authors.lastname: Qi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000628:therapy*; D016634:Radiosurgery / Q000379:methods*; D012074:Remission Induction; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D005641:Tegafur; D002945:Cisplatin; D002955:Leucovorin; D000093542:Gemcitabine